Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats

Fluids and Barriers of the CNS

Volumn 8, Issue 1, 2011, Pages

  Glage, Silke ^a   Klinge, Petra M ^b   Miller, Miles C ^b   Wallrapp, Christine ^d   Geigle, Peter ^d   Hedrich, Hans J ^a   Brinker, Thomas ^b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Neurosurgery Foundation   (United States)

^c INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^d CellMed AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN VENTRICLE; CAT; CELL VIABILITY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DURA MATER; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROCAPSULE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; STEM CELL GENE THERAPY; WATER PERMEABILITY;

EID: 80051713203     PISSN: None     EISSN: 20458118     Source Type: Journal    
DOI: 10.1186/2045-8118-8-18     Document Type: Article

References (31)

1. Tseng JL, Aebischer P. Encapsulated neural transplants. Prog Brain Res 2000, 127:189-202.
2. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001, 40:907-946. 10.2165/00003088-200140120-00003, 11735609.
3. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev 2001, 38:140-148.
4. Aird RB. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol 1984, 86:342-358. 10.1016/0014-4886(84)90192-4, 6548450.
5. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011, 8:7. 10.1186/2045-8118-8-7, 3042981, 21349155.
6. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp Neurol 2008, 209:82-88. 10.1016/j.expneurol.2007.08.019, 17963752.
7. Buchser E, Goddard M, Heyd B, Joseph JM, Favre J, de Tribolet N, Lysaght M, Aebischer P. Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience. Anesthesiology 1996, 85:1005-1012. 10.1097/00000542-199611000-00007, 8916816.
8. Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B, Bachmann C, Aebischer P. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant 2000, 9:471-484.
9. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, Palfi S, Nguyen JP, Bourdet C, Gaura V, Remy P, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004, 15:968-975. 10.1089/hum.2004.15.968, 15585112.
10. Murua A, Portero A, Orive G, Hernandez RM, de Castro M, Pedraz JL. Cell microencapsulation technology: towards clinical application. J Control Release 2008, 132:76-83. 10.1016/j.jconrel.2008.08.010, 18789985.
11. Orive G, Hernandez RM, Rodriguez Gascon A, Calafiore R, Chang TM, de Vos P, Hortelano G, Hunkeler D, Lacik I, Pedraz JL. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol 2004, 22:87-92. 10.1016/j.tibtech.2003.11.004, 14757043.
12. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002, 302:881-888. 10.1124/jpet.102.037481, 12183643.
13. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72:603-612. 10.1002/jnr.10611, 12749025.
14. Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett 2009, 463:176-181. 10.1016/j.neulet.2009.07.071, 19638295.
15. Klinge P, Harmening K, Miller MC, Heile A, Wallrapp C, Geigle P, Brinker T. Encapsulated native and Glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2011,
16. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002, 20:592-596. 10.1038/nbt0602-592, 12042863.
17. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 1998, 101:1334-1341. 10.1172/JCI610, 508688, 9502775.
18. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122:531-544. 10.1053/gast.2002.31068, 11832466.
19. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994, 134:2156-2164. 10.1210/en.134.5.2156, 8156917.
20. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179. 10.1038/nm919, 12925848.
21. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253-260. 10.1007/s00125-005-0107-1, 16416146.
22. Miyan JA, Zendah M, Mashayekhi F, Owen-Lynch PJ. Cerebrospinal fluid supports viability and proliferation of cortical cells in vitro, mirroring in vivo development. Cerebrospinal Fluid Res 2006, 3:2. 10.1186/1743-8454-3-2, 1450312, 16549001.
23. Visted T, Lund-Johansen M. Progress and challenges for cell encapsulation in brain tumour therapy. Expert Opin Biol Ther 2003, 3:551-561. 10.1517/14712598.3.4.551, 12831361.
24. Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?. Pharmacogenomics J 2006, 6:8-15. 10.1038/sj.tpj.6500337, 16314887.
25. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev 2001, 38:140-148.
26. Schwenter F, Schneider BL, Pralong WF, Deglon N, Aebischer P. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 2004, 15:669-680. 10.1089/1043034041361172, 15242527.
27. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006, 103:3896-3901. 10.1073/pnas.0600236103, 1383495, 16505355.
28. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J, Deglon N, Ouary S, Nimchinsky EA, et al. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 2000, 11:1177-1187. 10.1089/10430340050015220, 10834619.
29. Guan J, Beilharz EJ, Skinner SJ, Williams CE, Gluckman PD. Intracerebral transportation and cellular localisation of insulin-like growth factor-1 following central administration to rats with hypoxic-ischemic brain injury. Brain Res 2000, 853:163-173. 10.1016/S0006-8993(99)02030-2, 10640614.
30. Emmett CJ, Stewart GR, Johnson RM, Aswani SP, Chan RL, Jakeman LB. Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp Neurol 1996, 140:151-160. 10.1006/exnr.1996.0125, 8690058.
31. de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002, 41:691-703. 10.2165/00003088-200241100-00001, 12162757.